- Home
- BFST vs IMNM Comparison
BFST vs IMNM Comparison
Compare BFST & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFST
- IMNM
- Stock Information
- Founded
- BFST 2006
- IMNM 2006
- Country
- BFST United States
- IMNM United States
- Employees
- BFST N/A
- IMNM N/A
- Industry
- BFST Major Banks
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- BFST Finance
- IMNM Health Care
- Exchange
- BFST Nasdaq
- IMNM Nasdaq
- Market Cap
- BFST 783.9M
- IMNM 945.8M
- IPO Year
- BFST 2018
- IMNM 2020
- Fundamental
- Price
- BFST $23.98
- IMNM $10.75
- Analyst Decision
- BFST Strong Buy
- IMNM Strong Buy
- Analyst Count
- BFST 3
- IMNM 5
- Target Price
- BFST $30.00
- IMNM $26.40
- AVG Volume (30 Days)
- BFST 88.3K
- IMNM 965.4K
- Earning Date
- BFST 07-28-2025
- IMNM 08-11-2025
- Dividend Yield
- BFST 2.30%
- IMNM N/A
- EPS Growth
- BFST 3.92
- IMNM N/A
- EPS
- BFST 2.51
- IMNM N/A
- Revenue
- BFST $291,096,000.00
- IMNM $10,938,000.00
- Revenue This Year
- BFST $25.48
- IMNM N/A
- Revenue Next Year
- BFST $17.20
- IMNM $259.34
- P/E Ratio
- BFST $9.68
- IMNM N/A
- Revenue Growth
- BFST 17.48
- IMNM N/A
- 52 Week Low
- BFST $20.07
- IMNM $5.15
- 52 Week High
- BFST $30.30
- IMNM $16.81
- Technical
- Relative Strength Index (RSI)
- BFST 36.08
- IMNM 61.86
- Support Level
- BFST $24.45
- IMNM $10.33
- Resistance Level
- BFST $26.63
- IMNM $11.68
- Average True Range (ATR)
- BFST 0.68
- IMNM 0.62
- MACD
- BFST -0.29
- IMNM 0.08
- Stochastic Oscillator
- BFST 8.00
- IMNM 75.00
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.